Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose bismuth subcitrate for irritable bowel syndrome
IRCT2017081435691N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bismuth subcitrate in irritable bowel syndrome (IBS) and Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Isfahan University of Medical Sciences. Started Jun 2015; status: completed.
02
Drugs
bismuth subcitrate
03
Conditions
irritable bowel syndrome (IBS)Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on IRCT2017081435691N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017081435691N1.